{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:32:25Z","timestamp":1790821945752,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,10]],"date-time":"2014-08-10T00:00:00Z","timestamp":1407628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"Protalix Biotherapeutics"},{"name":"Office of the Chief Scientist of the Ministry of Industry, Trade and Labor, Israel","award":["51587"],"award-info":[{"award-number":["51587"]}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ymgme.2014.08.002","type":"journal-article","created":{"date-parts":[[2014,8,10]],"date-time":"2014-08-10T06:45:57Z","timestamp":1407653157000},"page":"259-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["Characterization of a chemically modified plant cell culture expressed human \u03b1-Galactosidase-A enzyme for treatment of Fabry disease"],"prefix":"10.1016","volume":"114","author":[{"given":"Tali","family":"Kizhner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaniv","family":"Azulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Hainrichson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Tekoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Arvatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avidor","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Ruderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aviezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoseph","family":"Shaaltiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2014.08.002_bb0005","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1152\/physiol.00041.2009","article-title":"Lysosomal storage disease: revealing lysosomal function and physiology","volume":"25","author":"Parkinson-Lawrence","year":"2010","journal-title":"Physiology"},{"issue":"4","key":"10.1016\/j.ymgme.2014.08.002_bb0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","article-title":"A case of \u201cAngeio-Keratoma\u201d","volume":"10","author":"Anderson","year":"1898","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01986897","article-title":"Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)","volume":"43","author":"Fabry","year":"1898","journal-title":"Arch. Dermatol. Syph."},{"issue":"1","key":"10.1016\/j.ymgme.2014.08.002_bb0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM197307052890103","article-title":"Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease","volume":"289","author":"Brady","year":"1973","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ymgme.2014.08.002_bb0030","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1073\/pnas.76.10.5326","article-title":"Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes","volume":"76","author":"Desnick","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2014.08.002_bb0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5483\/BMBRep.2013.46.3.192","article-title":"Enhanced sialylation and in vivo efficacy of recombinant human alpha-galactosidase through in vitro glycosylation","volume":"46","author":"Sohn","year":"2013","journal-title":"BMB Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2014.08.002_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1023\/A:1012451320105","article-title":"Enzyme replacement therapy in Fabry disease","volume":"24","author":"Brady","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2377-2-4","article-title":"Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.ymgme.2014.08.002_bb0060","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.ymgme.2014.08.002_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0070","doi-asserted-by":"crossref","first-page":"e000879","DOI":"10.1136\/bmjopen-2012-000879","article-title":"Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry M\u00fcnster Study (FaM\u00fcS) data","volume":"2","author":"Engelen","year":"2012","journal-title":"BMJ Open"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2014.08.002_bb0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2012.05.011","article-title":"Enzyme replacement therapy improves cardiac features and severity of Fabry disease","volume":"107","author":"Motwani","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"S111","key":"10.1016\/j.ymgme.2014.08.002_bb0080","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/ki.2008.522","article-title":"Renal manifestations in Fabry disease and therapeutic options","volume":"74","author":"Torra","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0085","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5414\/CNP71118","article-title":"The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function","volume":"71","author":"Aakre","year":"2009","journal-title":"Clin. Nephrol."},{"issue":"5","key":"10.1016\/j.ymgme.2014.08.002_bb0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/WCO.0b013e32834a9433","article-title":"Fabry disease","volume":"24","author":"Toyooka","year":"2011","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000336168","article-title":"Phenotype and genotype characterization and twin association in patients with Anderson\u2013Fabry cardiomyopathy","volume":"121","author":"Gomez","year":"2012","journal-title":"Cardiology"},{"issue":"5","key":"10.1016\/j.ymgme.2014.08.002_bb0100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1399-0004.2011.01671.x","article-title":"Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey","volume":"81","author":"Ramaswami","year":"2012","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0105","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","article-title":"Fabry disease in children: agalsidase-beta enzyme replacement therapy","volume":"83","author":"Borgwardt","year":"2013","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2014.08.002_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2014.08.002_bb0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0120","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1468-3083.2008.02638.x","article-title":"A study on serum IgE and clinical symptomatology of atopy in patients suffering from the lysosomal storage disorder Fabry disease","volume":"22","author":"Mohrenschlager","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"10","key":"10.1016\/j.ymgme.2014.08.002_bb0125","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase a in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2014.08.002_bb0130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2014.08.002_bb0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10545-013-9641-z","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease","volume":"37","author":"Pisani","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0140","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2119\/molmed.2011.00248","article-title":"Efficient uptake of recombinant \u03b1-galactosidase a produced with a gene-manipulated yeast by Fabry mice kidneys","volume":"18","author":"Tsukimura","year":"2012","journal-title":"Mol. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2014.08.002_bb0145","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.abb.2004.02.034","article-title":"Controlled glycosylation of therapeutic antibodies in plants","volume":"426","author":"Tekoah","year":"2004","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0150","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1006\/abio.1997.2199","article-title":"Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption\/ionization mass spectrometry and normal-phase high-performance liquid chromatography","volume":"250","author":"Kuster","year":"1997","journal-title":"Anal. Biochem."},{"issue":"5","key":"10.1016\/j.ymgme.2014.08.002_bb0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11103-012-9902-5","article-title":"Influence of an ER-retention signal on the N-glycosylation of recombinant human \u03b1-l-iduronidase generated in seeds of Arabidopsis","volume":"79","author":"He","year":"2012","journal-title":"Plant Mol. Biol."},{"issue":"5","key":"10.1016\/j.ymgme.2014.08.002_bb0165","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1042\/BSR20130081","article-title":"Glycosylation and functionality of recombinant \u03b2-glucocerebrosidase from various production systems","volume":"33","author":"Tekoah","year":"2013","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0170","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.ymgme.2014.08.002_bb0175","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0180","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54months of agalsidase therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0185","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00428-008-0586-9","article-title":"Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients","volume":"45","author":"Keslova-Veselikova","year":"2008","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.ymgme.2014.08.002_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2010.11.002","article-title":"The Fabrazyme shortage \u2014 A call to action for metabolic physicians","volume":"102","author":"Sirrs","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0195","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nbt0809-681a","article-title":"Virus stalls Genzyme plant","volume":"27","author":"Bethencourt","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2014.08.002_bb0200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2014.08.002_bb0205","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0021-9258(19)69965-5","article-title":"Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms","volume":"256","author":"Bishop","year":"1981","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ymgme.2014.08.002_bb0210","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00428-007-0468-6","article-title":"Cellular and tissue localization of globotriaosylceramide in Fabry disease","volume":"451","author":"Askari","year":"2007","journal-title":"Virchows Arch."},{"issue":"5","key":"10.1016\/j.ymgme.2014.08.002_bb0215","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2013","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"1","key":"10.1016\/j.ymgme.2014.08.002_bb0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am. J. Hum. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921400256X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921400256X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T23:01:39Z","timestamp":1649890899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671921400256X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S109671921400256X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2014.08.002","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of a chemically modified plant cell culture expressed human \u03b1-Galactosidase-A enzyme for treatment of Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2014.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}